The Medical Affairs Professional Society (MAPS) is honored to announce the inclusion of Janssen Pharmaceuticals, Inc. in the MAPS Industry Partnership Program (IPP), providing free MAPS membership and training resources for all Janssen Medical Affairs employees globally, as well as opportunities for Janssen leaders to collaborate with peers in other leading biopharmaceutical and medical technology organizations to set strategic direction for the Medical Affairs function.
“Janssen’s partnership with MAPS demonstrates both organizations’ commitment to excellence in Medical Affairs, from placing leaders in a position to influence the future of the profession, to optimizing the competencies of individual team members,” says Travis Hege, MAPS CEO.
Organizations involved in the MAPS IPP become part of a collaborative community of industry leaders and agents for progress in Medical Affairs. Program benefits include participation in regular Executive Consortium meetings for Chief Medical Officers and Global Medical Affairs Heads, priority invitations for senior leaders to participate on expert panels at MAPS Annual Meetings, and full access memberships to MAPS for all Medical Affairs employees in the organization company-wide. Membership also provides access to a community of peers as well as training resources including webinars, articles, best practices forums, eLearning modules, mentorship opportunities, and more.
Janssen joins existing MAPS Industry Partnership Program organizations Astellas, AstraZeneca, Bristol Myers Squibb, Eli Lilly & Co., Lundbeck, Mallinckrodt, Otsuka, Pfizer, Sanofi, Teva and UCB.
“As biopharmaceutical companies seek to deliver new medicines to new patient populations, the role of Medical Affairs is becoming increasingly important. MAPS is excited to grow with our industry partners and with the Medical Affairs function as a whole,” says Hege. “Together we are expanding the capabilities of the function to drive better outcomes for organizations and for patients.”